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Abstract
Whilst unsupervised injectable methadone and diamorphine treatment has been part of the British
treatment system for decades, the numbers receiving injectable opioid treatment (IOT) has been steadily
diminishing in recent years. In contrast, there has been a recent expansion of supervised injectable
diamorphine programs under trial conditions in a number of European and North American cities,
although the evidence regarding the safety, efficacy and cost effectiveness of this treatment approach
remains equivocal. Recent British clinical guidance indicates that IOT should be a second-line treatment
for those patients in high-quality oral methadone treatment who continue to regularly inject heroin, and
that treatment be initiated in newly-developed supervised injecting clinics.
The Randomised Injectable Opioid Treatment Trial (RIOTT) is a multisite, prospective open-label
randomised controlled trial (RCT) examining the role of treatment with injected opioids (methadone and
heroin) for the management of heroin dependence in patients not responding to conventional substitution
treatment. Specifically, the study examines whether efforts should be made to optimise methadone
treatment for such patients (e.g. regular attendance, supervised dosing, high oral doses, access to
psychosocial services), or whether such patients should be treated with injected methadone or heroin.
Eligible patients (in oral substitution treatment and injecting illicit heroin on a regular basis) are randomised
to one of three conditions: (1) optimized oral methadone treatment (Control group); (2) injected
methadone treatment; or (3) injected heroin treatment (with access to oral methadone doses). Subjects
are followed up for 6-months, with between-group comparisons on an intention-to-treat basis across a
range of outcome measures. The primary outcome is the proportion of patients who discontinue regular
illicit heroin use (operationalised as providing >50% urine drug screens negative for markers of illicit heroin
in months 4 to 6). Secondary outcomes include measures of other drug use, injecting practices, health and
psychosocial functioning, criminal activity, patient satisfaction and incremental cost effectiveness. The study
aims to recruit 150 subjects, with 50 patients per group, and is to be conducted in supervised injecting
clinics across England.
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Background
The British system of injectable opioid treatment
Conventional approaches to maintenance substitution
treatment using oral methadone are effective for most her-
oin users entering treatment (see [1] for review). However,
there are a proportion of patients who do not benefit from
such approaches – up to 50% of patients drop out of
maintenance treatment within 12 months, and of those
who remain in treatment, a substantial minority (up to
15% of most programs) continue to inject heroin on a reg-
ular basis (e.g. daily), and continue to experience consid-
erable drug related harm [2,3].
One response for those individuals who fail to benefit
from conventional substitution treatment has been the
prescription of injectable opioids – methadone and
diamorphine (pharmaceutical heroin). This has been a
distinctive, yet dwindling feature of the 'British system'
over the past 40 years [4]. The majority of patients treated
with injectable opioids have received injectable metha-
done ampoules, and much smaller proportions have
received injectable diamorphine (approximately 90% and
10% of injectable prescriptions in 1995 respectively [5]).
Unlike recent developments in Switzerland, Germany,
Spain and the Netherlands, where treatment centres have
been established to deliver supervised injectable opioid
treatment (IOT), the British system has had limited capac-
ity for supervised dosing. The majority of IOT patients
receive daily to weekly supplies of methadone or diamor-
phine ampoules from clinics or community pharmacies
for take home unsupervised consumption [6].
However, in the past decade, the role of IOT for heroin
dependence has been steadily diminishing in Britain.
Injected methadone ampoules accounted for 8.7% of
NHS opioid prescriptions for heroin dependence in Eng-
land and Wales in 1995, but only 1.9% in 2003 [4]. In
1995, diamorphine accounted for two per cent of all opi-
oid prescriptions for opiate dependence [5], and by 2000
this had fallen to approximately 1% [6]. Whilst exact
numbers are unavailable, we estimate that in 2006, there
are between 2,000 to 3,000 patients prescribed injectable
methadone ampoules, and up to 500 patients prescribed
diamorphine in the NHS for opioid dependence. This
total number in IOT has remained relatively static over the
past decade, with little 'turn-over' and few new patients
commencing IOT. Yet during this same period there has
been a marked expansion of numbers in opioid substitu-
tion (largely oral methadone and buprenorphine) treat-
ment in Britain, from fewer than 50,000 to over 100,000,
reflecting both a probable increase in the number of her-
oin users and the proportion in treatment. Thus, whilst
the number of heroin dependent users and the number of
patients entering substitution treatment in Britain appears
to be steadily increasing over the past decade, the role of
IOT has proportionally diminished, with few new patients
commencing this form of treatment. The diminishing role
of IOT in the UK may be due to a number of factors [6,7]:
- Limited evidence supporting IOT – the past decade has
seen an increasing emphasis within modern health sys-
tems that clinical activity be based upon the principles of
evidence-based practice [8,9]. Further, there is general
consensus as to the quality of evidence required to estab-
lish such an evidence base [10,11]. Whilst it is possible to
identify individuals or groups of clients who have been
successfully treated with IOT, this does not provide suffi-
cient evidence to establish the safety and efficacy of this
treatment approach. Adequately controlled trials, com-
paring IOT to treatment approaches considered 'gold
standard' for this patient population are required. Whilst
trials of heroin treatment conducted in Switzerland
[12,13] and the Netherlands [14] provide useful informa-
tion on the potential benefits of prescribing heroin, the
differences between the trial designs and treatment con-
text of these trials make it unclear how far these results can
be applied to a UK setting. Here in the UK, only one RCT
of 96 subjects conducted in the 1970's has compared
unsupervised IOT (diamorphine) to oral methadone
([15]- reviewed below). In contrast to the limited evi-
dence base of IOT, there has been an ever increasing body
of evidence supporting other substitution approaches,
such as oral methadone and sublingual buprenorphine
treatment.
- Concerns regarding diversion of medication – programs
with low levels of supervision may be less expensive to
deliver, however, widespread proliferation of treatment
programs without the capacity for supervision (even of
'unstable' patients) are likely to be associated with diver-
sion of some medication onto the 'illicit market'. Twelve
percent of patients in the Hartnoll trial [15] self-reported
selling part of their take away diamorphine ampoules. In
a recent survey of 192 opioid dependent patients entering
treatment in south London, approximately 20% reported
having ever used illicitly obtained injectable methadone
or diamorphine [16]. Doctors concerns over the possibil-
ity of diversion of prescriptions to others has led to a
reluctance by some to prescribe injectable treatments [6].
Concerns regarding diversion and poor adherence may
also limit the doses prescribed within IOT, which may in
turn reduce treatment effectiveness.
- Concerns that the provision of injectables may prolong
the drug use and injecting 'careers' of patients, with simi-
lar concerns that it is difficult to 'move' patients onto
more conventional treatment approaches once they have
been exposed to prescribed injectable opioids [15,17].
This can also result in 'silting up' of limited treatment
places, restricting its availability to new patients. This isHarm Reduction Journal 2006, 3:28 http://www.harmreductionjournal.com/content/3/1/28
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particularly relevant to the British system where the rou-
tine availability of injectable take-aways for unsupervised
consumption at home may remove incentives for clients
to move onto oral methadone programs.
- High cost – IOT is considerably more expensive than oral
methadone treatment. The main additional costs are med-
ication-related (e.g. approximate medication costs alone
(without VAT) for oral methadone (100 mg/day) are less
than £500 per year, £1500 per year for injectable metha-
done (100 mg/day), and £6500 per year using injectable
diamorphine (400 mg/day) licensed in the UK [18]; with
additional costs involved in dispensing and supervision.
In a London trial comparing supervised injectable to oral
methadone treatment, injectable treatment was found to
be 4 to 5 times more expensive to deliver [19]. Given the
increasing resource pressures placed upon health services,
and without evidence of its cost-effectiveness over con-
ventional treatment, IOT may be seen by many funding
bodies as an unaffordable 'luxury'.
Current evidence base for IOT
There have been several recent reviews of the evidence
base for IOT [20,21]. Three published RCTs have com-
pared injectable diamorphine to oral methadone; and one
has compared injectable methadone to oral methadone.
Hartnoll and colleagues [15] reported on treatment reten-
tion and self-reported heroin use in 96 heroin users enter-
ing treatment, randomised to either take-away
diamorphine ampoules (n = 44), or oral methadone (n =
52). Overall, self-reported heroin use was comparable
between the two groups. Whilst the injectable diamor-
phine group had significantly better treatment retention
at 12 months, the majority continued to use illicit heroin
in small amounts. In contrast, there was greater treatment
drop out in the oral methadone group, and some patients
stopped using illicit heroin, whilst others continued to use
larger amounts of heroin. The results did not demonstrate
a clear superiority for either treatment, and it was almost
20 years before the next controlled trial.
Perneger and colleagues ([12]) reported on the first RCT
of supervised injectable diamorphine, in which 51 Swiss
heroin users with a history of poor performance in prior
methadone programs were randomised to either injecta-
ble heroin (n = 24) or oral methadone (n = 27). Treatment
retention was high in both groups, and the heroin treat-
ment group self-reported significantly less heroin use than
the methadone group. However, a considerable propor-
tion of those randomised to oral methadone responded
well (33% achieving abstinence and 19% had very low
levels of heroin use), and 38% of patients randomised to
the oral methadone (wait list) Control group chose not to
enrol in diamorphine treatment when available six
months later. Initiating IOT would have been unnecessary
(and costly) in this patient group.
The experience from this RCT led to an understanding that
IOT should be seen as a 'second line' treatment approach,
generally confined to those patients who are failing to
respond to their current episode of methadone treatment.
This was the basis for the next RCT [14] conducted by the
CCBH in the Netherlands, in which 174 methadone
patients with a history of regular heroin injecting were
randomly allocated to either continue their oral metha-
done treatment (n = 98), or to commence injectable
diamorphine (n = 76) (with oral methadone doses also
available). Treatment retention was comparable, and the
injectable diamorphine group were reported to have had
a better global response in parameters such as social func-
tioning, psychological health and criminality.
These findings suggest that the addition of injectable
diamorphine conferred benefits to patients performing
poorly in methadone treatment over oral methadone
treatment alone. However, there were two key limitations
with the study. No data were reported for what are gener-
ally considered to be primary outcomes of treatment for
heroin dependence – levels of illicit heroin use and ongo-
ing high-risk injecting practices. We will return to this
issue later. More importantly however, the study did not
examine whether the addition of injectable heroin con-
ferred benefits over 'enhanced' or 'optimal' methadone
treatment. There were no specific attempts to optimise the
conditions of methadone treatment for those patients
randomised to the methadone only group. Hence, it may
be that some patients were performing poorly at enrol-
ment due to an inadequate methadone dose, poor psy-
chosocial services or infrequent attendance. Without
specific measures to optimize their treatment, it may not
be surprising that many continued to have poor out-
comes. Indeed the different outcomes between the two
randomized groups could be due to the considerable dif-
ferences in opioid doses used, and not due to the type or
route of opioid used (the mean methadone dose in the
Oral Methadone group was approximately 70 mg,
whereas the mean methadone equivalent dose in the
Injectable Diamorphine group was greater than 200 mg
daily). It should be noted that Hartnoll et al trial [15] had
a similar dose disparity (in the opposite direction, with
higher equivalent oral methadone than heroin doses),
thereby limiting the interpretation of two of the three
published RCTs.
There are many reasons why patients may continue regu-
lar heroin injecting during their methadone treatment.
These may be patient related (e.g. strong desire to con-
tinue injecting); alternatively, poor outcomes are often
related to how treatment is delivered. The components ofHarm Reduction Journal 2006, 3:28 http://www.harmreductionjournal.com/content/3/1/28
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effective methadone treatment are well established [22],
with more successful programs incorporating: higher
doses of methadone (in particular above 80 mg); ade-
quate levels of supervision and monitoring; access to psy-
chosocial services; and positive therapeutic relationships
between patients and service providers. In many treat-
ment systems, optimal treatment conditions are not
always available (such as access to adequate methadone
doses, counselling or welfare services), and under some
circumstances, continued heroin use by a patient in meth-
adone treatment can be reduced by enhancing the condi-
tions of their treatment – thereby diminishing the
indication for IOT for that individual.
The need for further research
The need for further controlled studies of IOT has been
highlighted by a number of clinicians, researchers, user
groups and political authorities (e.g. [7,19,23,24]). Sys-
tematic reviews of the evidence regarding IOT have con-
cluded (a) the provision of IOT in supervised injecting
clinics is feasible, (b) that IOT appears to be at least as
effective as conventional substitution treatment in achiev-
ing certain outcomes such as treatment retention; how-
ever (c) the existing evidence base is insufficient: "No
definitive conclusions about the overall effectiveness of
heroin prescription is possible because of non-compara-
bility of the experimental studies available. Heroin use in
clinical practice is still a matter of research in most coun-
tries" [20]. We note that there are several RCTs of injecta-
ble heroin treatment that have been recently conducted or
in progress (in Germany, Spain and Canada), and the
findings of these trials will substantially build upon the
available evidence base.
Given the concerns regarding IOT and its relatively lim-
ited evidence base, the principles of rational therapeutics
would suggest that IOT should be seen as a 'second line'
treatment modality limited to patients in methadone
treatment who meet the following criteria: (i) have a pro-
tracted history of heroin dependence and injecting, (ii)
have adhered to conditions of effective methadone treat-
ment for an extended period of time, yet (iii) continue to
regularly inject illicit heroin and experience related harms
[25]. To date however, no controlled trial of this target
group has adequately examined whether the prescribing
of injectable opioids is more effective than attempts at
enhancing the conditions of oral methadone treatment in
those patients performing poorly in their current treat-
ment episode.
Further, the social and historical context in which treat-
ment occurs must be considered. Recent guidance [25]
emphasises that all patients entering IOT should have full
supervised dosing (as with patients commencing oral sub-
stitution treatment), through the establishment of new
'European-style' clinical services. This is a new develop-
ment for UK services, and it may be that the feasibility of
delivering supervised IOT in Swiss, Dutch or German cit-
ies may be difficult to replicate in Britain, where there may
be different patterns of drug use, geo-demographics, and
importantly, different expectations among service users of
IOT – given the long tradition of unsupervised IOT in this
country.
Of particular relevance to the British setting is the limited
evaluation of injectable methadone treatment. The major-
ity of IOT in the UK is in the form of injectable metha-
done, and yet there has been only one RCT of injectable
methadone, a pilot study in which 40 heroin users enter-
ing treatment were randomly allocated to either equiva-
lent doses of oral methadone or injectable methadone.
There was no significant difference in treatment retention,
illicit heroin use or other outcomes between the two
groups [19]. The use of injectable methadone rather than
diamorphine may have particular advantages (e.g. only
one daily injection, less expensive) or disadvantages (e.g.
side effects, inadequate substitute for heroin). Further
research is required to establish the role of different inject-
able opioids.
Another concern in the interpretation of earlier research
has been the reliance on self-report data in evaluating
illicit heroin use. The research examining the validity and
reliability of self-reported heroin use (see [26] for review)
indicates that "self-report of illicit behaviours are suffi-
ciently reliable and valid to provide descriptions of drug
use, drug-related problems and the natural history of drug
use" (p. 261–262). However, the conditions required to
achieve this include that (a) there are no negatively per-
ceived consequences for the client arising from any self-
disclosure (such as loss of take-away privileges, loss of face
with a therapist or researcher, or even discontinuation of
the program); and (b) self-report coincides with, and can
be corroborated by, objective measures such as urine drug
screens. Hence, the evaluation of illicit heroin use in opi-
oid substitution treatment trials normally involves the
confidential collection of self-report data by independent
researchers, together with regular urine drug screens.
It is difficult to achieve these conditions when evaluating
diamorphine treatment. The detection of morphine in
urine drug screens (UDS) may be a suitable marker for
heroin use in methadone patients, but is useless as a
marker in diamorphine prescribed patients. Further, the
possible perception by some clients that unfavourable
outcomes for a trial-based diamorphine program could
result in its discontinuation or scaling back, could serve as
a motive for clients to under-report their illicit heroin use,
particularly in the absence of UDS. Under such circum-
stances, the validity and reliability of self-reported illicitHarm Reduction Journal 2006, 3:28 http://www.harmreductionjournal.com/content/3/1/28
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heroin use may be questioned. In response, there have
been efforts to establish objective measures of illicit her-
oin use that do not rely on the detection of morphine. A
promising technique includes the identification of
papaverine metabolites in UDS – papaverine is an opiate
found in illicit 'brown' heroin commonly used in western
Europe, but not present in pharmaceutical diamorphine
[27,28]. Recent research suggests papaverine metabolites
(hydroxy- and dihydroxypapaverine) are a suitable
marker for illicit heroin use, with high sensitivity, specifi-
city and negative predictive values compared to the detec-
tion of morphine in UDS of methadone or
buprenorphine prescribed patients [28]. This approach
provides an avenue for objective assessment of illicit her-
oin use in diamorphine-prescribed patients.
The development of the Randomised Injectable Opioid
Treatment Trial occurred as a response to calls from the
Home Office to expand IOT in Britain [24], the need to
better establish an evidence base for IOT, and to examine
the role of injectable methadone and diamorphine treat-
ment delivered under the conditions identified in new UK
national guidance [25]. Specifically, the central question
to be addressed is whether efforts should be made to opti-
mise conventional treatment for such patients (e.g.
encouraging high doses, supervised dosing, psychosocial
interventions, and regular attendance) in order to reduce
regular illicit heroin use, or whether such patients should
be treated with injected methadone or injected heroin in
newly developed supervised injecting clinics. To date, this
has not been addressed in published RCTs of IOT.
The research component of the trial was primarily funded
by a Research Grant from Action on Addiction, a national
voluntary sector charity and the Big Lottery. Clinical serv-
ices (including the establishment of new supervised
injecting clinics) were funded by the Home Office and
National Treatment Agency, together with local health
authority funding. The research is being conducted by
researchers at the National Addiction Centre (Institute of
Psychiatry, Kings College London and the South London
and Maudsley NHS Trust).
Methodology
Overview
RIOTT examines the role of IOT for the management of
heroin dependence in patients not responding to conven-
tional substitution maintenance treatment. The study is a
prospective, open-label three-way RCT (See figure 1). Eli-
gible patients (in oral methadone treatment but still
injecting illicit heroin on a regular basis) are randomised
to one of three conditions: (i) optimised oral methadone
treatment (Control group); (ii) injected methadone treat-
ment; or (iii) injected heroin treatment. Approximately
150 subjects (50 in each group) are followed up for 6-
months, comparing between-group differences on an
intention-to-treat analysis between the Control Group
and the Injectable Methadone Group, and between the
Control Group and the Injectable Heroin Group; compar-
Overview of Research Design for RIOTT Figure 1
Overview of Research Design for RIOTT.
6 months
Between group comparisons
Between group comparisons
Experimental Group
Injectable Methadone Group 
Control Group
Optimised oral methadone 
treatment
Experimental Group 
Injectable Heroin Group 
3 months
n=50
n=50
n=50
Subjects
x >3 years injecting 
x in treatment >6 months
x regular heroin injecting
x no active significant
medical / psychiatric
condition
x informed consent
N=150Harm Reduction Journal 2006, 3:28 http://www.harmreductionjournal.com/content/3/1/28
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ing outcomes across a range of measures, including drug
use, injecting practices, measures of global health and psy-
chosocial functioning, criminality, treatment retention,
incremental cost effectiveness, and measures of client sat-
isfaction. It is a multi-site trial conducted at four sites in
London (two sites), Brighton (South East England), and
Darlington (North East England).
Research hypotheses
The aim of the study is to examine the safety, efficacy and
cost effectiveness of treatment with optimised oral meth-
adone compared to injectable methadone or injectable
diamorphine, for patients in maintenance treatment who
continue to inject illicit heroin regularly. The trial is not
designed to directly compare injectable methadone to
injectable diamorphine treatment, which are both 'exper-
imental' conditions. Hence, the research hypotheses for
injectable heroin treatment are:
i) that a selected group of patients (not responding to cur-
rent oral methadone treatment) receiving injectable her-
oin treatment, will make greater reductions in their illicit
heroin use, other drug use and criminal activity, and
greater improvements in their health and social function-
ing, than if provided with optimised oral methadone
treatment;
ii) providing injectable heroin to a selected group of
patients (not responding to current oral methadone treat-
ment) results in a greater economic benefit per extra unit
of resource invested in the treatment, than only offering
optimised oral methadone;
iii) The formal null hypothesis is that: there is no differ-
ence between the two treatments
The research hypotheses for injectable methadone treat-
ment are:
i) A selected group of patients (not responding to current
oral methadone treatment) receiving injectable metha-
done treatment, will make greater reductions in their
illicit heroin use, other drug use and criminal activity and
greater improvements in their health and social function-
ing, than if provided with optimised oral methadone
treatment;
ii) providing injectable methadone to a selected group of
patients (not responding to current oral methadone treat-
ment) results in a greater economic benefit per extra unit
of resource invested in the treatment, than only offering
optimised oral methadone;
iii) The formal null hypothesis is that: there is no differ-
ence between the two treatments
The primary outcome measure is illicit heroin use as
measured by the proportion of subjects in each group who
cease regular illicit heroin use, operationalised as provid-
ing at least 50% UDS negative for markers of illicit heroin
during months 4 to 6 of treatment (allowing a sufficient
period for the study treatment to take effect). We estimate
at least 50% negative UDS in once weekly random UDS to
be consistent with no more than approximately one (or at
most two) days heroin use per week on average – which
represents a discontinuation of regular heroin use, and is
a clinically meaningful reduction for this particular
patient population (selection criteria include using illicit
heroin on at least 50% of days and 100% positive UDS
screens for heroin use). The full range of measures for
illicit heroin use is described in the Outcome Measures
section below.
The secondary outcome measures are:
- other illicit drug and alcohol use,
- high risk injecting practices and complications,
- indices of general health and psychosocial functioning,
- criminal activity,
- treatment retention,
- adverse events,
- cost-effectiveness in enhancing quality of life indices and
reducing illicit heroin use.
- patient satisfaction with each of the three treatment
approaches
- treatment goals and priorities of patients entering the
trial;
- likely demand for any future expansion of IOT under
these conditions.
Subjects
Selection criteria
The trial targets patients in methadone treatment who
continue to inject heroin on a regular basis. Specific crite-
ria are:
1. Aged between 18 and 65 years at recruitment to study.
2. At least 3-year history of injecting heroin use.
3. In continuous methadone treatment for at least 6
months this episode.Harm Reduction Journal 2006, 3:28 http://www.harmreductionjournal.com/content/3/1/28
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4. Regular injecting heroin use in preceding 3 months (as
evidenced by opiate-positive urine drug screens and self-
report in clinical records), and heroin use on at least 50%
of days (15 days) in the preceding month on self-report.
5. Evidence of regular injecting on clinical examination.
6. No significant and active medical (e.g. hepatic failure)
or psychiatric condition (e.g. active psychosis, severe
affective disorder).
7. Not alcohol dependent or regularly abusing benzodi-
azepines according to DSM-IVR criteria.
8. Not pregnant, breastfeeding, or planning to become
pregnant during the study period.
9. Resident of catchment area of participating agency.
10. Able and willing to participate in the study procedures
(e.g. no impending prison sentence) and provide
informed consent.
Sample and power calculation
Primary statistical comparisons will be made between the
Control and Injectable Methadone groups; and between
the Control and Injectable Heroin groups. The primary
endpoint for the sample size calculation is the proportion
of subjects in each group who cease regular illicit heroin
use (operationalised as providing at least 50% UDS nega-
tive for markers of illicit heroin) during months 4 to 6 of
treatment – allowing a sufficient period for the study treat-
ment to take effect.
Due to the differences in selection criteria and reported
outcome measures in previous studies of IOT, the availa-
ble evidence does not allow confident predictions of treat-
ment effect size for the different conditions. Nevertheless,
some estimates can be made based on earlier trials
[12,14,19,29]. Assuming 20% of subjects in the opti-
mized oral methadone group cease regular illicit heroin
use (as operationalised above), and 50% of patients in
each of the IOT groups cease regular illicit heroin use,
using a three-way randomisation schedule with equal
numbers assigned to each group, and with α = 0.05, β =
0.85, then approximately 50 subjects per group should be
sufficient to detect significant differences between the
Control group and each of the Experimental Injectable
groups – 150 subjects in total.
Recruitment and treatment allocation
Information regarding the trial is made available to
patients in participating catchment areas through a variety
of means, including written information at clinics, exist-
ing service providers, and through service user group
meetings. Patients receiving oral methadone treatment
who inject illicit heroin regularly may refer themselves, or
be referred by their keyworker to the RIOTT clinical team
at each site. Those identified as potentially eligible are
assessed and screened by RIOTT clinical staff to establish
eligibility and informed consent. The assessment, screen-
ing and consent process usually takes approximately two
weeks from initial presentation.
Randomisation for the trial is conducted independently
by the Clinical Trials Unit of the Institute of Psychiatry,
King's College London. Subjects are randomly allocated
using minimization techniques into one of the three study
conditions in a 1:1:1 ratio within each treatment site, with
stratification on two criteria: a) regular cocaine/crack use
(> 50% days in previous 4 weeks on self-report); and b)
receiving optimised oral methadone treatment at baseline
(doses of at least 80 mg/day and supervised at least 5 days/
week).
Randomisation occurs at the end of the two-week assess-
ment and consent period. Patients receive pre- and post-
randomization counseling by the clinical team prior to
being informed of their treatment allocation by a
researcher. Treatment is initiated on the next working day.
Treatment conditions
The study is an open-label trial in which clients, clinicians
and researchers are aware of treatment allocation. The
same clinical staff deliver all three treatment conditions at
each site, thereby minimizing the potential for bias as a
result of differences in staff expertise or enthusiasm. The
treatment conditions are:
(1) Optimised oral methadone treatment
Patients randomised to the Control group are to receive
'optimised oral methadone treatment'. The key principles
for treatment in this group entail:
- High methadone doses. Doses are individualised with the
aim of reducing illicit opiate use. Methadone doses in
excess of 80 mg (and generally >100 mg) are encouraged
(but not mandated) in this patient group, with a maxi-
mum upper dose of 300 mg identified.
- Supervised dosing: Oral methadone is consumed under
supervision on at least 5 days per week during the first 3
months. Thereafter, the level of supervised dosing may
reduce (conditional upon the patient's substance use,
medical, psychiatric and social circumstances) to three
days a week, which is the minimum attendance required
to enable random urine collection for drug screening.
-  Frequent reviews and ancillary services. Patients are
assigned a key worker, with weekly sessions scheduledHarm Reduction Journal 2006, 3:28 http://www.harmreductionjournal.com/content/3/1/28
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during the initial three-month period. Thereafter, the fre-
quency of scheduled reviews may reduce to two-weekly.
All patients have monthly reviews with a study medical
officer, and have access to a psychologist for individual
CBT-based therapy. Patients also have access to other
ancillary services (e.g. group programs) available at each
site, as for any patient of the service. It should be empha-
sized that participation in ancillary services such as coun-
seling or group activities are voluntary, and not a
requirement of continuation in the study.
- Treatment Care Plans addressing drug-related, physical,
psychological and social issues are developed in consulta-
tion with the client, key worker, study medical officer, and
other relevant parties within the first month of the study,
and reviewed at 3 and 6-months. Other health or social
services are engaged accordingly.
- Urine drug screens. Random urine drug screens collected
weekly.
(2) Treatment with Injectable Methadone or (3) Injectable 
Diamorphine
Aspects of treatment other than medication issues (such
as key worker and medical reviews, ancillary services, and
urine drug screens) are the same for the Injectable Metha-
done and Injectable Diamorphine groups as described for
the Optimised Oral Methadone Group.
- High doses of injectable methadone or diamorphine. For the
Injectable Methadone group, initial doses are converted
from oral to injectable methadone. Whilst there is limited
evidence regarding conversions between injected and oral
methadone in this population, the available data suggests
that oral methadone has a mean bioavailability of approx-
imately 80%, with large individual variation (ranging
from 40 to 100% in previous research) [30-33]. Hence,
the study uses a conversion formula of injected metha-
done dose = 0.8 × oral methadone dose (separate research
underway at the National Addiction Centre is examining
the biavailaibility of injectable methadone (IM and IV) in
long term oral methadone patients). Doses are subse-
quently titrated (generally upwards) and individualised
with the aim of reducing illicit opiate use. Patients can
also choose to have oral methadone supplements. Maxi-
mum doses of injectable methadone are 200 mg per day
(plus up to 100 mg oral methadone), to a total dose of
300 mg per day.
Injectable Diamorphine group: the dose conversions
between oral methadone and injected diamorphine are
based upon the work of Seidenberg and colleagues [34],
developed for the Swiss, and more recently used by the
German and Canadian heroin trials. The dose equivalence
between oral methadone and diamorphine is not linear.
At low doses, the conversion rate from oral methadone
(total daily dose) to injected heroin (total daily dose) is
approximately 1:3; whilst at higher doses, the conversion
rate approximates 1:5. Other factors that impact upon
methadone metabolism (e.g. concomitant medications,
medical conditions) are taken into consideration at trans-
fer. Doses are subsequently titrated and individualised
with the aim of reducing illicit opiate use. Patients are
encouraged to retain a small oral methadone dose (e.g. 20
to 40% of their initial dose) in order to prevent opiate
withdrawal between injecting sessions, and to facilitate
any transitions between oral methadone and injected
diamorphine (effectively having a 'loading dose' of meth-
adone). It is expected that most patients will use injected
diamorphine doses in the range of 300 to 600 mg per day,
with an upper total daily dose of 900 mg (450 mg per
injection). Patients can also have up to 100 mg oral meth-
adone supplementary to diamorphine, making their total
oral methadone equivalent dose approximately 300 mg.
- Supervised dosing. All doses of prescribed injectable opio-
ids are supervised throughout the 6-month study period.
Treatment typically involves once-a-day injection of
methadone, or twice-a-day injection of diamorphine.
Patients have a degree of autonomy in the frequency of
attendance for dosing and the mix of injected opioids/oral
methadone – patients unable or unwilling to attend for
injectable opioid treatment have access to oral methadone
doses. This flexibility of attendance for on-site injecting
aims to minimize the inconvenience of IOT, and reflects
that many patients entering RIOTT may not be injecting
every day, and hence, it may not be therapeutically neces-
sary for patients to increase their frequency of injecting.
An example of this dosing flexibility is provided in Table
1. Patients must attend a minimum of 4-days-a-week for
onsite IOT (to ensure integrity of the treatment condi-
tion). The principles of IOT used in RIOTT are consistent
with recent national guidance [25].
All doses of injectable opioids are supervised onsite in the
participating clinics. Two injecting sessions operate each
day, 7-days a week. Patients self-administer their injec-
tions, with the choice of intravenous, intramuscular or
subcutaneous routes. Injecting sites and routes are
Table 1: Example of flexibility in IOT prescription
Drug & route Dose & time
Regime A Diamorphine (IV or IM)
Diamorphine (IV or IM)
Methadone (oral)
200 mg morning
200 mg afternoon
30 mg evening
Regime B Diamorphine (IV or IM)
Methadone (oral)
200 mg (daily)
100 mg (daily)
Regime C Methadone (oral) 160 mgHarm Reduction Journal 2006, 3:28 http://www.harmreductionjournal.com/content/3/1/28
Page 9 of 13
(page number not for citation purposes)
recorded daily, and routinely assessed throughout the
trial.
Medications
Trial medications include (i) oral methadone solution (1
mg in 1 ml) or concentrate (10 mg in 1 ml); (ii) injected
methadone ampoules (50 mg in 1 ml, 50 mg in 2 mls, 10
mg in 1 ml ampoules licensed in the UK for IM or IV injec-
tion); and (iii) diamorphine: the trial uses 10 gram freeze-
dried diamorphine ampoules licensed and imported from
Switzerland (Diaphin®), which are reconstituted by a trial
pharmacist under aseptic conditions to a concentration of
100 mg/1 ml. Each injection of diamorphine is dispensed
as a 'loaded' syringe by the pharmacist, and self-injected
by the patient. The trial has a Clinical Trial Authorisation
from the UK Medicine and Health Regulatory Authority
for importation and use of Diaphin® ampoules.
Treatment post-trial
As injectable methadone and injectable diamorphine are
licensed and available in Britain, the trial does not need to
consider issues of 'compassionate grounds' for continua-
tion of treatment. At the end of the 6-month study period,
the nature of ongoing treatment is decided on an individ-
ual basis by clinicians in consultation with each patient,
in keeping with the recent NTA Guidance Report [25], and
subject to available clinical resources. The basis of this
decision will be the extent to which each patient has dem-
onstrated a positive clinical response and has obtained
significant benefit from their study treatment.
Outcome measures and data collection
The study utilises a combination of data collection meth-
ods for the outcome domains, including self-report data,
UDS, and clinical records. Structured interviews with sub-
jects are conducted by independent (IoP) researchers at
baseline (during the pre-trial treatment phase), 3 and 6
months after randomisation. Semi-structured interviews
are conducted at various time points over the trial.
Efficacy
The primary outcome for the trial is illicit heroin use,
measured using self-report data and UDS results, using
papaverine metabolites as markers of illicit heroin use
[28]. The secondary outcomes include changes in other
types of substance use, high-risk injecting practices, indi-
ces of general health and psychosocial functioning, crimi-
nal activity, treatment retention, and indices of patient
satisfaction. Outcome measures are described in Table 2.
Safety
Adverse events to injected prescription heroin have been
described in Swiss heroin clinics [35], however further
information comparing the adverse profile of injected
diamorphine, oral and injected methadone in chronic
addict populations is needed to better characterise the
safety profile of these medications. Adverse events may
occur as a result of the drug (e.g. methadone, heroin), or
the route of administration (IV, IM, oral). Indeed, anecdo-
tal reports suggest that some patients experience consider-
able adverse reactions (e.g. pain, 'burning') with
Table 2: Outcome measures
Outcome Outcome measures
Illicit heroin use • Self-reported data at 3 and 6 month interviews (including number of days used, routes of 
administration, average amount/cost, and frequency of use in past month as measured by the 
Opiate Treatment Index (OTI) Q score [43]; self-reported overdoses.
• Random weekly UDS result, testing for papaverine metabolites.
Other drug use • Self-reported data at 3 and 6 month interviews regarding use of other opioids, alcohol, 
benzodiazepines, cannabis, cocaine. Measures include number days used, average cost/amount 
used.
• Random weekly UDS result
High-risk injecting practices • Self-report data at 3 and 6 month interviews regarding participation in risk practices for 
blood borne virus transmission in preceding month using modified Injecting Risk Questionnaire 
[44]
• Self-report data regarding injecting practices in past month (including sites, routes, adverse 
events, complications) and clinical examination of injecting sites (monthly medical reviews)
General health status and psychosocial functioning • Self-report data using SF-36 [45], EQ-5D [46, 47] and OTI Psychosocial Adjustment Section 
collected at 3 and 6 month interview
• Hospital Anxiety Depression Scale [48] completed at monthly medical review.
Changes in criminality • Self – report data using modified Crime Section of Maudsley Addiction Profile [49] and OTI 
collected at 3 and 6 month interview
Measures of patient expectation and satisfaction • Treatment Perceptions Questionnaire [50]
• Drug Use Expectations and User Nominated Outcome Instrument structured and semi-structured 
interviews examining patient perceptions of positives and negatives of using illicit heroin, and 
key outcomes/goals of treatment, as identified by service users (developed for the trial). 
Interviews conducted with service-user researcher at baseline, 3 and 6 months
• Semi-structured interviews with service-user researcher examining patient perspectives of 
the relative advantages and disadvantages of each of the three treatment approaches.Harm Reduction Journal 2006, 3:28 http://www.harmreductionjournal.com/content/3/1/28
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intravenous methadone, however these have not been
adequately documented in the published literature.
RIOTT will examine adverse events between the three
treatment groups over time.
There are also potential concerns regarding the cardio-res-
piratory effects of injectable opioids. Previous studies
examining self-administration of injectable heroin and
methadone have identified significant hypoxia in some
patients [36,37]. However, it is unclear to what extent the
risk of hypoxia is influenced by treatment conditions (e.g.,
injected drug, route of administration, dose). There have
also been recent concerns regarding the use of high dose
(oral and injected) methadone and prolongation of QTc
intervals, a condition associated with cardiac arrythmias
(such as torsade de pointes) and sudden death [38,39]. It
remains unclear whether injected methadone poses a
greater risk of QTc prolongation than equivalent doses of
oral methadone. The acute effects of injected diamor-
phine upon ECG changes have not been previously
reported. To address these concerns, indices of respiratory
and cardiac function are examined in relation to the drugs
used (methadone versus diamorphine), route of adminis-
tration (oral, IV and IM), and dose, compared to pre-ran-
domisation baseline measures.
The prescription and supervised injection of diamorphine
(and methadone) allows the opportunity to study the
physiological, subjective and cognitive-performance
effects of these drugs. Despite widespread use of injected
heroin in many societies, there is to date remarkably little
published literature about the impact of injected heroin
or methadone upon these parameters. The capacity to
study the effects of heroin under clinical/laboratory con-
ditions will enhance our understanding of the acute
effects of heroin use in dependent users.
Another aspect of safety of this treatment approach is that
of 'community safety'. One of the major issues facing
those providing drug treatment services is the possible
community backlash when such services are proposed
within a local community. The establishment of a super-
vised injecting clinic raises potential concerns for the local
community. Examples may include fears of local residents
and businesses regarding the congregation of drug users
regularly attending the clinic; or concerns regarding intox-
icated clients being a nuisance to the local community. As
a part of the overall RIOTT, a community impact evalua-
tion will be conducted to: a) investigate the impact on the
local community of supervised injectable maintenance
clinic; b) document the expectations, fears and experience
of the local community; and c) compare and contrast the
methods used by different services for addressing commu-
nity interaction. The study design incorporates a blend of
epidemiological and social research methodologies in
order to gather data from a number of complimentary
sources.
Cost effectiveness
IOT is likely to be more expensive than optimised oral
methadone treatment, yet may be associated with better
outcomes and/or cost-savings elsewhere. The economic
evaluation will take a broad cost perspective, including
costs borne by the health, social, voluntary and criminal
justice sectors, and costs to the economy in the form of
productivity losses. Detailed information on the resources
associated with the three treatment interventions are col-
lected from the relevant clinics and include staff time,
equipment, study medications, dispensing services and
the treatment of adverse events. Data on the use of all
other services (including health, social and voluntary sec-
tor services), days off work due to illness, criminal justice
sector contacts and crimes committed are collected using
a service use schedule, based on one designed at the Uni-
versity of York for the economic evaluation of alcohol and
drug interventions and successfully applied to evaluations
of brief interventions [40]. Self-report data are collected at
research interviews at baseline and at the 3 and 6 month
follow-up points. Cost-effectiveness will be explored in
terms of illicit heroin use, the primary outcome measure,
and in terms of quality adjusted life years, using the EQ-
5D measure of health-related quality of life (see Table 2).
Patient satisfaction and experiences
A service-user researcher (CH) employed through a service
user-organisation, the Alliance, conducts structured and
semi-structured interviews with subjects throughout the
follow-up period to gain information on expectations of,
and satisfaction with treatment (see Table 2). Semi-struc-
tured interviews will also explore the broader experience
of prescribed and non-prescribed heroin use, exploring
the contextual influence of the clinical setting itself in the
construction of individual's experiences of heroin use. It is
expected that interviews with a service user researcher may
lend greater validity to subject responses when examining
issues such as treatment goals, perceptions about illicit
heroin use and treatment.
Data analysis
Quantitative data will be recorded by hand in Case Record
Forms, coded, and entered into a database using the Sta-
tistical Package for Social Science-12 software by a
researcher. Data will be analyzed on an intention-to-treat
basis. The primary outcome measure (illicit heroin use –
operationalised as the proportion of subjects who provide
>50% UDS negative for markers of illicit heroin use dur-
ing the 4th to 6th months of study treatment) will be ana-
lysed using the logistic regression model. Continuous
outcomes collected at 3 time points (baseline, 3 months
and 6 months follow-ups), will be modelled usingHarm Reduction Journal 2006, 3:28 http://www.harmreductionjournal.com/content/3/1/28
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repeated measurement with mixed models approach to
examine the differences between treatment and control
groups and the time course. Correlated responses will be
dealt with by covariance structures. Endpoints that are
coded as categorical data will be treated as multivariate
binary responses in order to fit the repeated measure-
ments. Odds ratios will be used to present differences in
treatment retention between the control and IOT groups.
Semi-structured interviews collecting qualitative data are
tape recorded (with subject consent) and transcribed,
with all identifying information removed from the tran-
scripts. Data is analysed in hard copy form, using qualita-
tive thematic analysis [41].
Discussion
Despite IOT being part of the British treatment system,
there have been few studies examining the safety and
effectiveness of this approach, particularly of injectable
methadone treatment, which comprises the majority of
IOT in this country. The primary aim of RIOTT is to com-
pare the safety, efficacy and cost effectiveness of injectable
methadone and diamorphine treatment (delivered under
supervised conditions), to optimised oral methadone
treatment, in methadone patients who regularly inject
illicit heroin. Such research should better inform clini-
cians and policy makers as to how to respond to this
patient group, and to inform decision making as to
whether additional resources should be directed to IOT,
or to enhancing the capacity for oral methadone treat-
ment to be delivered under optimised conditions.
The establishment of RIOTT also enables a variety of
'nested' studies examining a range of issues regarding
injectable heroin and methadone. Some of these studies
have been briefly discussed, such as projects examining
the cardio-respiratory effects of these drugs in chronic opi-
ate dependent individuals. Other projects being examined
include cognitive-performance effects of injectable opio-
ids compared to oral methadone, and pharmaco-genetic
research examining responses to opioid treatment.
Despite the widespread proliferation of heroin use across
the world, and despite reports of widespread misuse of
methadone by injection [42], there has been remarkably
little laboratory research examining the pharmacological
effects of these drugs at high doses in chronic opiate users.
Such research may lead to a better understanding of the
mechanisms behind heroin-related harms such as cogni-
tive impairment and overdose.
A key point in embarking on another RCT of injectable
heroin treatment relates to the extent to which there is a
sufficient evidence base currently available to scientifi-
cally 'prove' the efficacy of heroin prescribing – in short –
do we need more heroin trials? Underlying this is the
question 'how much evidence is required in order to sci-
entifically establish the efficacy and safety of a particular
treatment'? The experience of substitution opiate treat-
ment (methadone, LAAM, buprenorphine) suggests that
considerable and unequivocal evidence is required in
order to defend such treatments against politicised critics
– be they politicians, academics, service providers, local
community or (ex)drug user groups – much more so than
in most other areas of medicine. This applies to an even
greater extent with the highly controversial issue of inject-
able opioid prescribing. A particularly strong evidence
base will be a minimum requirement in establishing IOT
as an available option – the findings of two or three RCTs
alone are unlikely to convince sceptics of such a conten-
tious treatment paradigm. The most recent systematic
Cochrane review of heroin prescribing suggests that differ-
ences in study design limit our capacity to draw conclu-
sions on the available published trials in this area. The
completion and dissemination of the various interna-
tional trials in Germany, Spain, Canada and Britain is
required in order to establish this evidence base, particu-
larly as we should not pre-empt the findings of such stud-
ies in assuming that they will all show similar results.
Should the broad safety and efficacy of IOT be established
through the various trials underway internationally, it will
enable researchers to address the next 'level' of clinical-
research questions. This may include issues around the
availability of take-away doses of injectables, the selection
of which opioids should be prioritised, and whether
patients can be successfully transitioned from injecting to
non-injecting (e.g. intranasal, oral) routes.
We should also recognise that, as with the expansion of
methadone and buprenorphine treatment internationally
over the past 20 years, any expansion of IOT will often be
preceded by calls for 'local' research that addresses local
concerns and regulatory requirements. Interestingly,
whilst Phase III RCTs are often conducted in order to
achieve registration of a new medicine, in the British con-
text however, licensing of IOT is not the issue. Rather
research is required to establish its role within the treat-
ment system after over a decade of decline, and at a time
where health systems are requiring a greater evidence base
of efficacy and cost-effectiveness.
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